OPTIMIZATION OF ANTIDOTISM IN CASES OF SKIN INJURIES CAUSED BY BLISTER AGENTS. EXPERIMENTAL STUDY

MIHAI-SILVIU TUDOSIE 1, SIMONA BICHERU 2, RUXANDRA AVRAM 3, OANA AVRAM 1,3, CAMELIA ANDREEA VÂRZARU 2, CRISTINA ANCA SECARĂ 2, DRAGOȘ ŞERBAN 1,4,5, GABRIEL CĂTÂLIN SMARANDACHE 1,4, CIPRIAN TÂNĂSESCU 1, DRAGOȘ MARIAN POPEȘCU 6, CORNELIU TUDOR 4, ANA MARIA DASCĂLU 1, CRISTINEL DUMITRU BADIU 1,7

1“Carol Davila” University of Medicine and Pharmacy Bucharest, Romania
2“IVth Department of General Surgery, Emergency University Hospital Bucharest, Romania
3“Lucian Blaga” University of Medicine and Pharmacy Sibiu, Romania
4“Cantacuzino” National Medical Research-Development Institute Bucharest, Romania
5University of Medicine and Pharmacy Craiova, Romania
6“Carol Davila” University of Medicine and Pharmacy Bucharest, Romania
7Department of General Surgery, “Bagdasar-Arseni” Emergency Hospital Bucharest, Romania

*corresponding author: dragos.serban@umfcd.ro

Abstract

The molecular mechanisms involved in the appearance of oedema and blisters induced by the mustard gas are not fully elucidated, which justifies the difficulty of identifying effective medical countermeasures for the treatment of skin lesions. The paper aims to compare the skin toxicity produced by the chemical compound mustard gas and its synthetic analogue 2-chlorethyl-ethyl sulphide (CEES), as well as the development and experimental testing of a transdermally absorbed therapeutic formula, whose components pharmacodynamically antagonize the toxicity of these compounds. The experimental results highlighted the following: the synthetic analogue 2-chlorethyl-ethyl sulphide (CEES), due to its lower toxicity, is a valid alternative for the laboratory study of blistering chemicals; in vitro evaluation of cell viability in case of CEES exposure revealed cytotoxicity correlated with the dose partially antagonized by the administration of the complex antidote; contamination of the skin with doses of 4.5 µL/cm² mustard gas and 10 µL/cm² CEES, respectively, did not produce aggressions such as chain breaks in the DNA; the in vivo assessment of the toxicity of mustard and its synthetic analogue CEES revealed that the administration of the complex antidote showed 30% protection for mustard gas and 100% for CEES in case of percutaneous administration of the average lethal dose (LD50). The histopathological examination showed that the therapeutic effect generated on chemically assaulted areas is predominant by limiting ulcers and inflammation.

Rezumat

Mecanismele moleculare implicate în apariția edemului și a vesciculilor induse de compusul mustard gas nu sunt complet elucidate, ceea ce justifică dificultatea identificării unor contramăsuri medicale eficiente pentru tratamentul leziunilor cutanate. Lucrarea își propune evaluarea comparativă a toxicității cutanate produse de compusul chimic mustard gas și de analoogul său sintetic 2 clor-etil-etil sulfură (CEES), precum și realizarea și testarea experimentală a unei formule terapeutice cu absorbție transdermică, ale cărei componente să antagonizeze farmacodinamic toxicitatea acestor compuși. Rezultatele experimentale au evidențiat următoarele aspecte: analoogul sintetic CEES, datorită toxicității mai reduse, reprezintă o alternativă validă pentru studiul în laborator al agentilor chimici vezicanti; evaluarea in vitro a viabilității celulare în cazul expunerii la CEES a evidențiat citotoxicitate corelată cu doza parțial antagonizată de administrarea antidotului complex; contaminarea tegumentelor cu doze de 4.5 ţăl/m⁴ mustard gas și respectiv 10 µL/cm² CEES nu a produs agresiuni de tipul rupturilor cutanare la nivelul ADN; evaluarea in vivo a toxicității iperice și a analoogului său sintetic CEES a evidențiat că administrarea antidotului complex a determinat o protecție de 30% pentru mustard gas și 100% pentru CEES în cazul administrării percutane a dozei letale medii (DL50). Examenul histopatologic a evidențiat faptul că efectul terapeutic generat pe zonele agresate chimic este predominant de limitare a ulcerărilor și a inflamației.

Keywords: mustard gas, 2-chlorethyl-ethyl sulphide (CEES), toxicity, antidote

Introduction

Vesicants are chemical compounds that produce serious toxic effects on the eyes, lungs and skin through direct contact or inhalation of vapours [18]. They represent a family of compounds based on sulphur, nitrogen and oxygen, with similar chemical and biological properties [12]. Their toxicity is determined by the presence of the central sulphur atom and the terminal chlorine group [10, 32]. Nitrogen-containing blister agents are known for their use as chemotherapeutic drugs, and sulphur blister agents are best known for their applications in armed conflicts [18]. The prototype
of the latter class is mustard gas, by its chemical name bis(2-chloroethyl) sulphide.

The molecular mechanisms involved in the occurrence of oedema and blisters induced by the mustard gas compound are not fully elucidated, which justifies the difficulty of identifying effective medical countermeasures for the treatment of skin lesions [7, 8, 11, 12, 34]. Also, there are no experimental studies to prove the existence of a specific treatment for skin lesions caused by mustard gas [18, 24-26]. This context justifies the synthesis and characterization of a synthetic analogue of mustard gas with similar but less toxic properties, namely 2-clorehthyl-ethyl sulphide (CEES) [1, 2].

The paper proposes as specific objectives the comparative assessment of skin toxicity produced by the chemical compound mustard gas and its synthetic analogue, 2-clorehthyl-ethyl sulphide (CEES), as well as the development and experimental testing of a transdermal absorbed therapeutic formulation, whose components are able to antagonize the toxicity of these blistered compounds.

**Materials and Methods**

**Materials and reagents**

Mustard gas - vesicant chemical compound, 83% purity, product in the custody of the Center for Scientific Research for Defence CBRN and Ecology Bucharest, Romania; 2-clorehthyl-ethyl sulphide (CEES) 97% purity, Sigma-Aldrich, German; 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability determination kit, Sigma-Aldrich, Germany; Phospho-Histone H2A.X Antibody (CR55T33), Alexa Fluor 488, Thermo-Fisher, USA.

The following medicines were used to obtain the composition of the complex antidote: infliximab (Inflectra®, Pfizer Europe, Belgium); dexamethasone (Dexametasona fosfat KRA® 4 mg/mL, Krka, Czech Republic); ketoprofen (Ketoprofen Rompharm® 50 mg/mL, Rompharm, Romania); N-acetylcyesteine (Flumucil® 100 mg/mL, Zambon, Italy).

The following formula were used to obtain the composition of the complex antidote: infliximab (Inflectra®, Pfizer Europe, Belgium); dexamethasone (Dexametasona fosfat KRA® 4 mg/mL, Krka, Czech Republic); ketoprofen (Ketoprofen Rompharm® 50 mg/mL, Rompharm, Romania); N-acetylcyesteine (Flumucil® 100 mg/mL, Zambon, Italy).

The formula of the complex antidote is the following: ketoprofen 5%, dexamethasone 0.4%, N-acetylcyesteine 30%, Infliximab 1%, PEG 400 20 mL and water for injections ad 100 mL.

**In vitro cytotoxicity studies**

For in vitro cytotoxicity studies of vesicular compounds, using a MTT kit, a stock solution of 2 chloro-ethyl-ethyl sulphide (CEES) was prepared by dissolving 347 µL CEES solution of 97% concentration in 9.53 mL dimethylsulfoxide (DMSO). From this stock solution, the working solution of concentration 6 mM/300 µL was prepared by dissolving 1 µL stock solution in 9 mL DMSO.

**Laboratory equipment**

EnSight multimodal reader™ Multimode Microplate Reader (Perkin Elmer, USA), used for optical density reading in the MTT method for determining cell viability using MTT cell proliferation kit; confocal microscope, Zeiss LMS 980 (Zeiss, Germany), used to identify focii H2 AX (phosphorylated histone H2AX - antibody) on tissue using the technique of fluorescence microscopy; Zeiss Axioslab 5 light microscope (Zeiss, Germany) for histopathological examination of skin samples using haematoxylin-eosin staining (HE); gas chromatograph coupled to mass spectrometer GC/MS/MS 18-01 (Thermo Electron Corporation, UK), Trace Gold capillary column 30 m x 0.25 mm x 0.25 µm (Thermo Scientific); EXIGO H 400 veterinary haematology analyser (Boule Diagnostics; Sweden).

**In vitro evaluation of the cytotoxicity CEES using the MTT cell viability assay**

An experimental in vitro toxicity assessment model of CEES was performed by incubating a fibroblast culture, NIH/3T3 ATCC® CRL-1658™ (ATCC, USA) (10⁶ cells/mL) with 100 µL (2 mM CEES) of S1 solution of 2-chloroethyl sulphide and cytotoxicity testing using the MTT kit. The therapeutic efficacy of the complex antidote according to the protocol presented below was also tested in vitro under the same conditions.

Thus, for the cytotoxicity test of CEES the fibroblast cell line cultured in 25 cm² cell culture vessels using Dulbecco's Modified Eagle's Medium (DMEM) (ATCC, USA) supplemented with 10% foetal bovine serum (FBS) (Thermo-Fisher, USA) and 50 µg/mL gentamicin. Cells were trypsinized with 0.025% trypsin-EDTA, (Sigma-Aldrich, Germany) were centrifuged and the pellet resuspended in 5 mL of complete DMEM medium. Initial cell counting was performed by staining with Tripin Blue (Sigma-Aldrich, Germany) 1:1 (50 µL cell suspension + 50 mL Tripin Blue).

The cell suspension had a concentration of 1.07 x 10⁶ cells/mL. To perform the cytotoxicity test, the cell suspension was cultured in a 96-wells microplate, 200 µL/well (2.14 x 10⁶ cells/well) and incubated in a 5% CO₂ atmosphere at 37°C for 24 hours with 100 µL of CEES S1 solution, or with 100 µL S1 solution and 100 µL complex antidote, respectively. 30 µL MTT/well (10% of the volume of medium) was added and incubated for 4 hours at 37°C in a CO₂ atmosphere. After 4 hours, the microplate was removed from the incubator, the medium was removed and the MTT solvent was added (200 µL/well). The optical density was read at a wavelength of 570 nm, up to one hour after the addition of the solvent. The samples were performed in triplicate.

The following formula is used to evaluate the results:

\[
\% \text{ cellular viability} = \frac{(\text{OD positive control} - \text{OD blank})}{(\text{OD negative control} - \text{OD blank})} \times 100
\]

where: Positive control 1 = cells + CEES + MTT + solvent MTT; Positive control 2 = cells + CEES + complex antidote + MTT + MTT solvent; Negative
control = cells + MTT + MTT solvent; blank = medium (DMEM complete) + MTT + MTT solvent; OD = optical density.

**In vivo evaluation of the toxicity of the synthetic analogue CEES and the efficacy of the treatment**

The laboratory animals were young male BALB/c mice (approx. 4 months old), weighing 25 - 30 g, country of origin Romania, kept in microclimates adequately in compliance with the legislation in force on animal welfare. The diet was balanced, consisting of standard granulated food. The temperature, humidity and ventilation of the environment were controlled by the specialized staff of the biobase who permanently monitored the animals. The project received the Animal Ethics Commission Approval within the Medical-Military Research Centre, Bucharest, Romania.

An experimental *in vivo* toxicity model of the mustard gas and the synthetic analogue CEES was performed under the administration of toxic substances and of the complex antidote by using 5 groups of 5 mice epilated at the dorsal region on an area of approx. 4 cm², as follows: Group 1 (control), to which a volume of 0.5 mL/cm² complex antidote was applied to the epilated dorsal region. Group 2, to which 4.5 µL/cm² mustard gas of 83% purity (1 LD50 percutaneous) were applied, corresponding to the consumption norm according to AEP 58 (5 g/m²) at the level of the epilated dorsal region. Group 3, to which 4.5 µL/cm² mustard gas was applied and immediately, a dose of 0.5 mL/cm² complex antidote at the level of the epilated dorsal region. Group 4, to which CEES was applied in a dose of 10 µL/cm² (1 LD50 percutaneous) at the level of the epilated dorsal region. Group 5, to which CEES was applied at a dose of 4.5 µL/cm² (1 LD50) and immediately a dose of 0.5 mL/cm² complex antidote at the level of the epilated dorsal region.

This way of comparing the control group with the intoxicated and treated groups was chosen because the mortality of the animals was monitored. The project received the Animal Ethics Commission Approval within the Medical-Military Research Centre, Bucharest, Romania.

**Histopathological examination**

All animals in the 5 groups were examined. Surviving animals were euthanised (CO₂ inhalation) at 7 days and fragments of skin and liver were sampled for assessment by histopathological techniques of the severity of lesions caused by the mustard gas vesicant compound and CEES, respectively. Three 9-mm-diameter wounds were made on the back, at the previously epilated dorsal region. These were full-thickness wounds at the superficial level. The haematoxylin-eosin staining (HE) technique was used for paraffin sections.

**Statistical analysis**

Statistical analysis was performed using Microsoft Excel 2010 software (Microsoft Corp., USA) and GraphPad Prism v. 5.0. (GraphPad Software, USA). The Student’s T test was used for statistical analysis of all the experimental results with quantitative values. Results are expressed as mean ± standard deviation.

**Results and Discussion**

**In vitro evaluation of the cytotoxicity of CEES using the MTT cell viability assay**

The Student’s T test statistical analysis of the experimental results shows that the average values of the optical density corresponding to the cell viability of the cell solution, medium and MTT differ statistically significantly from the mean of the values corresponding to the cells treated with CEES solution 2 mM/100 mL. (Table 1).

<table>
<thead>
<tr>
<th>No.</th>
<th>Control</th>
<th>Optical density</th>
<th>CEES concentration (mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Negative control*</td>
<td>0.535 ± 0.017</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>Positive control 2</td>
<td>0.172 ± 0.019</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>Positive control 2 ***</td>
<td>0.385 ± 0.013</td>
<td>2</td>
</tr>
</tbody>
</table>

* cells, MTT solvent and MTT; **cells + CEES + MTT + solvent MTT; ***cells + CEES + complex antidote +MTT + MTT solvent

The statistical analysis of the experimental results showed that the average values of the optical densities of the positive control 1 intoxicated with 2 mM CEES and untreated differ statistically significantly from the ...
average values of the negative control considered control (p = 0.0002) as well as the average values of the optical densities of positive control 2, intoxicated with 2 mM CEES and treated with the complex antidote (p = 0.009). The synthetic analogue CEES shows a direct cytotoxic effect highlighted by the MTT test; cytotoxicity partially improved by the administration of the complex antidote. The cell viability when administering CEES-S1 solution (2 mM) was 26.98% and of 69.81%, when administering CEES S1 solution and complex antidote.

**In vivo assessment of toxicity of mustard gas and its synthetic analogue CEES**

The results of the in vivo studies are presented in Table II.

### Table II

<table>
<thead>
<tr>
<th>Group</th>
<th>LD50 Mustard gas (µL/cm²)</th>
<th>Synthetic analogue (CEES) (µL/cm²)</th>
<th>Complex antidote (mL/cm²)</th>
<th>Percentage mortality at 72 hours</th>
<th>Percentage mortality at 7 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>-</td>
<td>0</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>4.5</td>
<td>0</td>
<td>0.5</td>
<td>30%</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>4.5</td>
<td>0</td>
<td>0.5</td>
<td>30%</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>0</td>
<td>10</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>0</td>
<td>10</td>
<td>0.5</td>
<td>0</td>
</tr>
</tbody>
</table>

The comparative analysis of the 7-day percentage mortality under the percutaneous application of the average lethal dose shows that, without treatment, the vesicant mustard gas is approximately 2 times more toxic than its synthetic analogue CEES (60% mortality compared to 30% in the case of CEES). The application of the treatment in the case of the chemical compound vesicant mustard gas prolongs the duration and increases the survival rate by protecting in proportion of 30%. In the case of the synthetic analogue CEES, the application of the treatment protects 100%.

### Histopathological examination

All skin fragments from all the 5 study groups underwent histopathological examination. The results were correlated with the applied chemicals. Within each group similar types of lesions were observed, but with slight variation in the severity. The animal with most severe lesions was chosen for presentation. The experimental results highlighted the following aspects:

**Group 1** - non-intoxicated, treated only with the complex antidote (fragment of skin taken from the dorsal region with a thickness of approximately 10 microns): at the level of the skin layers, the histopathological exam showed no solutions of continuity, inflammatory or haemorrhagic elements (Figures 1a and 1b), and the skin appendages are present and have a normal appearance.

**Groups 2 and 4** intoxicated with 1 LD50 chemical compound vesicant mustard gas (group 2) and respectively synthetic analogue CEES (group 4) and untreated: the patterns of cellular aggression exerted at the skin level secondary to exposure to mustard: interface dermatitis with vacuolar and lichenoid type, spongiform and bullous dermatitis (with or without acantholysis), alteration of the derm/hypoderm ratio by sclerodermiform changes. The predominant lesions in the cases of subjects exposed to chemical aggression were superimposable on chemical necrosis with biological features expressed by: the presence of a predominantly acute inflammatory infiltrate, consisting of PMNs and rare macrophages, extended from the hypodermic level, including peri-adnexal and in the band adjacent to the basal layer; vascular congestion in the deep layers, secondary to the irritative effect; basal layer cell hyperplasia, with mitotic figures and cytoplasmic vacuolization; thickening of the spinous layer, with the appearance of acanthosis and highlighting the intercellular junctions, alternating with areas of acantholysis; thickening of the granular and horny layer by increasing the necrotic elements and implicitly the acceleration of the cutaneous cellular turnover; bacterial colonized fibrinoid-hematic crust, oedematous underlying connective tissue (Figures 2a and 2b).

Groups 3 and 5 intoxicated with 1 LD50 mustard gas (group 3) and CEES (group 5) and treated with the complex antidote: histopathological examination shows skin fragments with lesions secondary to the stressor (mustard gas) with areas of skin dilaceration and continuity solutions covered by fibrino-hematic crust, bacterially colonized. Compared to untreated subjects, there is a limitation of inflammatory infiltrate and ulcers, with an impact on the granulation tissue that does not have neoformation vessels, inflammatory elements or fibroblasts. Adjacent to the chemically induced trauma, hyperplasia of the spy layer is observed due to the predominance of the dermal papillae and of the adjacent squamous layer, constituting areas of acanthosis.
Figure 1.
a) colour HE, 20X. skin fragment, without continuity solutions or inflammatory or haemorrhagic infiltrate; 
b) HE coloration, 40X

Figure 2.
a) histopathological lesions in lot 2 (gas mustard): HE, 20 X. Fibrin-hematic crust developed in the segment of continuity of the skin. Adjacent. The area of acanthosis (top right) and acantholysis (underlying the crust) with a bullous appearance. Inflammatory infiltrate existing up to the hypodermic level, where capillary congestion and rare blood extravasations are observed; b) histopathological lesions in lot 4 (CEES): HE, 40X. skin that shows the thickening of all layers, with the amplification of the basal layer, at the level of which cytoplasmic clarifications are partially identified, and linear and diffuse inflammatory infiltrate, similar to prickly dermatitis; of the spinous layer where areas of acanthosis and obvious desmosomal junctions are identified; the granular and horny layer are thickened due to the acceleration of cell turnover through necrosis generated by the chemical and bacteriological impact

Figure 3.
a) HE, 20X Skin with fibrin-hematic crust; adjacent, acanthosis with hyperplasia of the dermal papillae; b) blisters in the area of skin ulceration, with minimal adjacent inflammatory infiltrate
GC-MS analyses to identify residual amounts of mustard gas at skin level

Representative chromatograms of the samples from animals exposed to mustard gas (coded CBRN/L1/2020/S1, with a peak area of 353,371,135 units) and animals exposed to mustard gas and antidote (coded CBRN/L1/2020/ST1, with a peak area of 171,237,277 units) are presented in Figure 4 and Figure 5, respectively.

Figure 4.
Total ion chromatogram of CBRN/L1/2020/S1

Figure 5.
Total ion chromatogram of sample CBRN/L1/2020/ST1

The analysis of the areas of the compound of interest in the two samples showed that after the application of the complex antidote the amount of toxic found in the ST1 sample is reduced to half of the amount with which the subjects were marked. The complex antidote could neutralize the residual toxic compound on the skin surface due to N acetylcysteine, an antioxidant compound that donates SH groups.

The chemical compound mustard gas is a highly toxic vesicant in case of skin exposure, the pathogenic mechanisms being multiple and still a subject of research. The molecular mechanisms involved in the pathogenesis of skin aggressions produced by the mustard gas compound and its synthetic analogue CEES are the consequence of their alkylating, pro-oxidizing and of inflammation mediators activating properties [3-5, 14, 33]: oxidative aggression by GSH depletion and increased nitric oxide synthesis [5]; nitric oxide (NOS) synthetases from mononuclear phagocytes and neutrophils are also important mediators involved in the pathogenesis of inflammation. The mechanism of up-regulation of iNOS expression leads to increased synthesis of nitric oxide (NO), a strong oxidizing agent. [27]; irreversible damage to the DNA strand: alkylation of guanine at position N7 and adenine at position N3 which have the effect of producing G-C to A-T transitions during replication, lethal at the cellular level [25]; activation of cyclooxygenase-derived prostaglandins (COX and COX-2) [9, 32]; activation of proinflammatory cytokines (IL6, TNFα) [34].

The clinical manifestations related to mustard gas exposure occur with a latency of several tens of minutes or hours, depending on the dose and the mode of exposure [21]. The lethal oral dose for humans is 200 mg. The most common manifestations occur in the eyes, respiratory system and skin. Initially, the exposed subject perceives a faint smell of sulphur or garlic. At 30 - 60 minutes, nausea, vomiting and eye pain and tearing appear. The eyes are extremely sensitive to mustard gas toxicity, even low doses may provide incapacitation and visual impairment. In cases of exposure to less than 50 mg/min/m², mild conjunctivitis and corneal swelling. After several hours of exposure, at a concentration of 200 mg/min/m² or more, the corneal oedema becomes severe, significantly decreased vision or even temporary blindness. Increased concentration of mustard gas leads to damage of limbal
stem the exposed skin should be washed

dicity of mustard gas, its

dimately after treatment.

An antidote formula for topical use has been developed
to speed recovery. In severe and exte

the vesicles and necrotic lesions is considered useful

vessels that become coalescent, forming large sheets of

1% and pain and itching control with general

local hyperaemia in the first hours,

signalling the beginning of epithelial healing.

The skin lesions appear 2 - 24 hours postexposure,

being characterized by itching, pain and burning

sensation, with local hyperaemia in the first hours,

followed by serous-haemorrhagic blisters usually after

24 hours [17, 27, 29]. Blisters developed from small

vesicles that become coalescent, forming large sheets of

epithelium, with secondary hydro-electrolytic

impairment [20, 27]. In the following 2 - 6 days, there is a significant risk of wound infection. If correct

managed, the healing process starts after 10 - 50 days,

with pigmentary changes that may remain for months or years [29, 30].

As general management, all victims should be removed from the exposure area as soon as possible, clothes removed and the exposed skin should be washed abundantly with water and soap with neutral pH. If eyes are exposed, lavage with large quantities of Ringer or saline solution are necessary to remove the toxic. Up to date, there is no local or systemic antidotes for mustard gas exposure. Experimental studies showed that parenteral administration of a combination of sodium thiosulfate (3000 mg/kg), vitamin E (20 mg/

kg), or dexamethasone (8 mg/kg) within 15 minutes of exposure may reduce the associated tissue and organ damages. The pharmacological effect combines the scavenger role of thiosulfate for alkylant agents such as mustard gas, with antioxidants effects of vitamin E and anti-inflammatory action of corticosteroids. However, the use was not employed in human treatment of mustard gas intoxications. N-acetylcysteine administered orally a maximum dose of 600 mg/daily, or 1200 mg/daily, 1800 mg/daily, showed in clinical trials clinical improvements of lung function, though longer evidence is needed to be prescribed in current practice [1, 27, 28, 31].

Local management of skin wounds involves, in the first stage limiting inflammation by corticosteroids ointments, preventing bacterial superinfection using a topical bacteriostatic agent, such as silver sulphadiazine 1% and pain and itching control with general or local medication. Pain may be controlled with mild analgesic and antihistaminic [9] drugs in mild to moderate intoxications, but requires narcotics (morphine sulphate) in severe cases. Topical combinations based on phenol 1% and menthol 1% or capsaicin (0.025%) showed partial relief of pain and pruritus in exposed patients [30]. Surgical or laser dermal debridement of the vesicles and necrotic lesions is considered useful to speed recovery. In severe and extensive burn, skin graft may be required, after debridement[22, 27, 29].

An antidote formula for topical use has been developed in the present study, which has been shown to be effective in limiting the skin toxicity of mustard gas. Due to the increased toxicity of mustard gas, its synthetic analogue CEES, has been a valid experimental alternative for scientific research studies on the pathogenic mechanisms involved and the identification of effective therapeutic solutions. [2, 14, 26], In vitro evaluation of cell viability in case of CEES exposure revealed cytotoxicity correlated with the dose partially antagonized by the administration of the complex antidote.

The complex antidote was formulated so that through its components it would pharmacodynamically antagonize the toxic effects of the chemical compound mustard gas and its synthetic analogue. The amount of residual toxic vesicant compound identified by the GC-MS technique after application of the toxicant to laboratory animals was halved immediately after treatment. In vivo evaluation demonstrated that the administration of the complex antidote showed 30% protection for mustard gas and 100% for CEES in the case of percutaneous administration of the average lethal dose (1 LD50). Histopathological examination showed that the therapeutic effect generated on chemically assaulted areas is predominant by limiting ulcers and inflammation. Further studies, on human subjects are needed to establish the adequate therapeutic doses and the possibility of a personalized treatment for greater efficacy [23].

Conclusions

The experiment demonstrates the type of lesions induced by exposure to mustard (ulceration with abundant diffuse inflammatory infiltrate, arranged to the deep layers), the lesion pattern being predominantly lichenoid and bullous. The therapeutic effect generated on chemically aggressed areas is predominant characterized by limiting ulcers and inflammation, but without succeeding in total remission of the necrosis foci formed, due to the high degree of toxicity of blister agents. The results are encouraging, but further studies, on large number of subjects are necessary before testing the efficiency of the developed antidote on human patients.

Conflict of interest

The authors declare no conflict of interest.

References


4.  Bielefeldt KA, Amini-Nik S, Alman BA, Cutaneous wound healing: recruiting developmental pathways...


